Monday, February 4, 2008 January Focus Pick Update Immunosyn Corporation (BB: IMYN) Latest Green Baron Pick Up on News! Douglas A. McClain, Jr. Resumes CFO Duties at Immunosyn January Focus Pick IMYN closes at $3.15 per share on Friday up over 20% since our profile price on Jan. 24 of $2.61 per share Much Bigger Move Still Expected to Come! The Green Baron Report maintains that our latest pick IMYN continues to set up for a big move higher. The stock rallied again on Friday to close on the day high at $3.15 per share up another .15 per share on the day and over 20% since our profile price less than two weeks ago. We expect Immunosyn to continue to attract attention for development of its lead drug compound SF-1019 to treat a variety of disorders and complications. Technically, IMYN has been making higher lows since early January. In late November last year, IMYN rallied to hit $7 per share, and we are hoping to see this kind of move again now that an uptrend appears to be confirmed. Click the following link to see: BigCharts IMYN. LA JOLLA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) has announced that Douglas A. McClain, Jr., will resume the duties of CFO effective February 1, 2008. Mr. McClain also serves as the Company's Chairman of the Board and Corporate Secretary. At the same time Immunosyn announced the resignation of G. David Criner as the company's Chief Financial and Accounting Officer. Mr. Criner, hired in October 2007, is leaving due to family matters. "We appreciated David's expertise through this first leg of our development and welcome Douglas A. McClain, Jr. back in his former role as CFO. In the interim we have initiated a candidate search for a permanent CFO," commented Stephen D. Ferrone, CEO and President of Immunosyn Corporation. About Immunosyn Corporation La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and Diabetic Ulcers (DU). Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company's filings with the Securities and Exchange commission, including risks summarized in the company's annual Report of form 10-K for its most recent fiscal year. The Company's actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments. SOURCE Immunosyn Corporation Contact: Bill Kraus, Lisa Baker or Devon Blaine all of The Blaine Group Phone (310)360-1499 Fax: (310)360-1498 for Immunosyn Corporation
|
